A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder Save

Date Added
November 5th, 2019
PRO Number
Pro00091292
Researcher
Jennifer Jones

List of Studies

Silhouette
Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

The purpose of the study is to examine whether an investigational medication called ketamine, which comes in the form of a nasal spray, is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

Institution
MUSC
Recruitment Contact
Jennifer Jones
(843) 792-5594
jonjen@musc.edu

Change_preferences

-- OR --

Create_login